Effect of a drug Mitomycin C in repair of tear ducts

Efficacy of Mitomycin C in External Dacryocystorhinostomy-A Randomized controlled trial - MED study(Mitomycin in External DCR)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/02/003352

Enrollment

Registered

2013-02-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Primary acquired nasolacrimal duct obstruction in adults

Interventions

Intervention1: Mitomycin C: The Mitomycin group will receive intraoperative 0.4mg/ml mitomycin to the osteotomy site for 5 minutes. Control Intervention1: Saline solution: Normal Saline solution is a

Eligibility

Inclusion criteria

Inclusion criteria: Participants who are of age 18 years and above with Primary acquired nasolacrimal duct obstruction

Exclusion criteria

Exclusion criteria: 1.Secondary causes like deviated nasal septum,nasal polyps,atrophic rhinitis 2. Revision DCR/Stents 3. Renal failure or immunosuppression 4. Pregnancy and lactation 5. Out station patients 6. Participants not willing to consent

Design outcomes

Primary

Measure	Time frame
Success rates of External Dacryocyctorhinostomy (Ext-DCR) with and without intraoperative Mitomycin C (MMC) at 3 months post operatively.Timepoint: Success rates of External Dacryocyctorhinostomy (Ext-DCR) with and without intraoperative Mitomycin C (MMC) at 1 week,1 month and 3 months post operatively.	—

Secondary

Measure	Time frame
NilTimepoint: nil	—

Countries

India

Contacts

Public ContactVINOD JOSHUA JOHN

Christian Medical College

saradadavid@gmail.com04163071201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026